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 بلقلا ضحم ينتورب زيكرت ىلع ةنمزلما دبكلا ضارمأ يرثأت
مدلا في طبارلا نيهدلا
سكوف ثيك ،مايليو تنيرب ،يداهلا ظيفح 
 ةطللجا صيخشتل اهلامعتسا نكيم يتلا ةديدلجا ةيويلحا-ةيئايميكلا تارشؤلما دحأك طبارلا ينهدلا بلقلا ضمح ينتورب فرعي :فدهلا  :صخللما
 دبكلا ضارمأ ريثأت ةنراقم وه ةساردلا نم فدهلا .دبكلا يف طبارلا ينهدلا بلقلا ضمح ينتورب دوجو ىلع ليلد نلآا ىتح دجوي لا . اركبم ةيبلقلا
 فيلتلا ضرمو يئابولا دبكلا باهتلا لثم ةنمزلما دبكلا ضارمأ ريثأت ةسارد تم :ةقيرطلا .مدلا يف طبارلا ينهدلا بلقلا ضمح ينتورب ىوتسم ىلع
 وه يرايعلما  فارحنلاا ±رمعلا  طسوتم )  ضارملأا هذه نم نوناعي صاخشأ ةرشع دنع طبارلا  ينهدلا  بلقلا  ضمح ينتورب  ىوتسم ىلع يدبكلا
 ىضرلما يف (ينبوريليبو يننَلالأا ِينَمأ َُةلِقان ،طبارلا ينهدلا بلقلا ضمح ينتورب) ةيلاتلا تانيتوربلا و تايمزنلأا زيكرت ةسارد تم .(ةنس 7,19 ± 58,33
 (ةنس 8.0 ± 63.8 وه يرايعلما فارحنلاا ±رمعلا طسوتم ،مدلاب اعربتم نيرشع نم ةنوكم ءاحصلأا نم ةطباض ةعومجم عم اهزيكرت ةنراقم و
 بلقلا ضمح ينتورب :)يرايعلما فارحنلاا ± طسوتلما( يلاتلاك ةيضرلما ةعوملمجا عم ةنراقم ةطباضلا ةعوملمجا يف داولما هذه زيكرت ناك :جئاتنلا .
 198,67 لباقم رتل / ةدحو  ± 14.7 29.8 يننَلالأا ِينَمأ َُةلِقان ،رتل /مارجوركيم 3,06 ± 6,44 لباقم رتل /مارجوركيم 2,21 ± 6,86 طبارلا ينهدلا
 .)P > 0.0001 ( رتل / لوموركيم 87,85 ± 100,89 لباقم رتل / لوموركيم 9.6 ± 4.0 ينبوريليبلا و ، )P> 0.0005  (رتل / ةدحو 122,89 ±
 دبكلا ضارمأب ةباصلإا ةجيتن طبارلا ينهدلا بلقلا ضمح ينتورب زيكرت ىوتسم ىلع ماه ريثأت كانه دجوي لا هنا حوضوب تانايبلا هذه ينبت :ةصلالخا
 يف طبارلا ينهدلا بلقلا ضمح ينتوربل عفانلا مادختسلاا معدت ةساردلا هذه .مدلا يف دبكلا تايمزنأ و تانيتورب يف حضاولا عافترلاا نم مغرلا ىلع ،
.ةنمزلما دبكلا ضارمأب ينباصلما ىضرلما  ىدل بلقلا ةلضع ةباصإ صيخشت
 .ينبوريليب ، يننَلالأا ِينَمأ َُةلِقان ،طبارلا ينهدلا بلقلا ضمح ينتورب ،ةنمزلما دبكلا ضارمأ :تاملكلا حاتفم
abstract: Objectives: Heart-type fatty acid binding-protein )H-FABP( has been reported to be a potential novel 
biochemical marker for the early diagnosis of acute myocardial infarction )AMI(. The presence of H-FABP in the liver 
has not been reported. The aim of this study was to compare the effect of chronic liver diseases on the level of H-FABP 
concentrations. Methods: The effects of chronic liver diseases including infective hepatitis and cirrhosis on the concentration 
of H-FABP was studied in a small group of patients )n=10, mean age ±SD = 58.33 ± 7.19 years(. The serum concentrations 
of the following markers were measured: H-FABP, alanine aminotransferase )ALT( and bilirubin and compared with a 
reference control group )20 healthy blood donors, mean age ±SD = 63.8 ±8.01(. Results: The serum concentrations of these 
markers in the control group as compared to patients with chronic liver disease were as follows )mean ± SD(: H-FABP = 
6.86 ±2.21 µg/L versus 6.44 ±3.06 µg/L )p = NS(; ALT = 29.8 ±14.7 U/L versus ALT = 198.67 ±122.89 U/L )p < 0.0005( and 
bilirubin = 9.6 ±4.0 µmol/L versus bilirubin = 100.89 ±87.85 µmol/L )p < 0.0001(. Conclusion: These data illustrate clearly 
that there is no significant interference with the normal concentration of H-FABP in the presence of liver diseases, despite 
the significant elevation of liver enzymes and proteins. These data may support a useful role of H-FABP for the diagnosis 
of myocardial injury in patients with liver diseases.
Keywords:   Heart-type fatty acid-binding protein )H-FABP(; Chronic liver diseases; Bilirubin; Alanine aminotransferase.
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Faculty of Medicine, University of Edinburgh, UK. 3University of Edinburgh, Cardiovascular Research Unit, Royal Infirmary of 
Edinburgh, UK.
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Advances in Knowledge
1. Heart-type fatty acid-binding protein is a useful early marker for the diagnosis of acute myocardial infarction. 
2. The effect of chronic liver diseases on the diagnostic potential of this marker is not known. 
3. This article illustrates the lack of interferences of the various types of chronic liver diseases on the ability to use heart-type fatty acid 
binding-protein as an early cardiac marker for the early diagnosis of acute myocardial infarction.
Application to Patient Care
1. The information provided in this article will help health institutions caring for patient’s with acute myocardial infarction on how best 
to use, interpret and apply the results obtained with heart-type fatty acid-binding protein in patients presenting with acute chest pain 
suggestive of evolving acute myocardial infarction who also have various co-existing types of chronic liver diseases.
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Heart-type fatty acid binding- protein (H-FABP) is a small soluble non-enzyme protein composed of 132 amino 
acids.1 It is one of the most abundant proteins in 
the heart and comprises 5-15% of the total cytosolic 
protein pool. H-FABP exists in high concentrations 
in the heart; however, this protein is not totally 
cardiac specific and occurs in other tissues although 
in a much lesser concentrations.2,3 H-FABP was 
introduced by Glatz et al. in 1988 as a potential 
novel biochemical marker for the early diagnosis 
of acute myocardial infarction (AMI).4 This was 
soon confirmed in many other studies.5-9 Some of 
the more recent studies have questioned the value 
of these early markers (H-FABP and myoglobin) 
when compared with specific markers like cardiac 
troponin I (cTnI).10 
H-FABP is released into plasma within 2 hours 
after symptom onset and is reported to peak at 
about 4-6 hours and return to normal base line value 
in 20 hours.7 Within the period of 30-210 minutes 
after symptom onset, H-FABP has > 80% sensitivity 
for the diagnosis of AMI.11 Within the interval of 
0-6 hours after symptom onset, the other cardiac 
markers such as creatine kinase (CK), CK-MB mass 
or activity, cTnI and T (cTnT) will only be starting 
to accumulate in the plasma, and their sensitivity 
has been reported to be around 64%.12
The exact route(s) of excretion of H-FABP from 
the circulation is not fully understood. As suggested 
by previous studies, the kidney may be the major 
route of excretion of H-FABP from circulation. A 
rise in serum and urine H-FABP concentration above 
normal values is seen in patients who present with 
AMI as early as 1.5 hours after symptom onset.13 
Studies in animals have also shown decreased 
myocardial tissue content and rising plasma and 
urine concentrations of H-FABP very early after 
coronary artery ligation.14-15 H-FABP circulates for a 
longer time (> 25 hours) after AMI in the presence 
of renal failure.11 
The presence of H-FABP in the liver has not been 
reported. However, an isoform specific to the liver 
called liver-type FABP exists.16 The interferences 
of this protein and chronic liver diseases on the 
concentration of H-FABP has not been studied 
before. Also, the effect of chronic liver diseases on 
the release of H-FABP from other tissues has not 
yet been fully evaluated.17 Therefore, the aim of the 
study was to compare the effect of chronic liver 
diseases on the serum levels of H-FABP.
Methods 
The effects of disease states in particular chronic 
liver diseases on the normal concentration of 
H-FABP was studied in 2003-2004 a small group of 
patients with a mixture of chronic liver disorders 
(n=10, mean age ±SD = 58.33 ±7.19 years, range 
45-70 years, median = 59 years) These patients had 
a range of conditions including infective hepatitis 
and cirrhosis (chronic hepatitis B = 2, chronic 
hepatitis C = 2, chronic alcoholic hepatitis = 3, 
other cirrhosis = 3). They were recruited from the 
Liver Unit at the Edinburgh Royal Infirmary, UK. 
Ethical approval was obtained from the local ethical 
committee (Lothian Research Ethics Committee, 
Edinburgh) and informed consent was obtained 
from each patient before beginning the study. The 
study complies with the Declaration of Helsinki. 
The serum concentrations of the following markers 
H-FABP, ALT and bilirubin were measured in the 
study group and compared with the concentrations 
of these markers in a normal reference control 
group of healthy blood donor controls (n=20, mean 
age ±SD = 63.8 ±8.01, range 53-75 years, median 
= 65 years). Peripheral blood samples for serum 
analysis were collected in white Starstedt Monovette 
vacutainer tubes by venepuncture. The blood 
samples (5mls) were taken through a peripheral line 
(intravascular access). The extracted samples were 
allowed to clot at room temperature for 1 hour and 
then centrifuged at 4°C, and the resulting serum was 
divided into small aliquots and frozen at -70°C until 
analysis. H-FABP was analysed by an enzyme linked 
immunosorbent assay method using commercially 
available assays (Hycult, Cambridge).17 Bilirubin 
and ALT were measured in the Biochemistry 
Department of the Edinburgh Royal Infirmary on 
an automated analyser machine using commercial 
assays. 
Statistical analyses were performed using the 
Statistical Package for Social Sciences (SPSSTM, 
Pittsburgh, Version 15). Continuous variables 
were presented as mean ± standard deviation. 
Comparisons between the study group and control 
group variables were conducted by the Mann-
Whitney U test for continuous variables. Significant 
results were indicated by probability values less than 
or equal to 0.05.
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Results 
The analytical sensitivity of H-FABP assay (mean 
± 2SD) was 0.206 ±0.047 g/L.17 The normal 
concentrations of these markers in the normal 
reference control group of healthy blood donor 
controls were as follows: H-FABP = 6.86 ±2.21 
µg/L; ALT = 29.8 ±14.7 U/L and bilirubin = 9.6 ±4.0 
µmol/L. The study group consisted of 10 patients. 
The concentration of these markers in patients with 
chronic liver diseases were as follows: H-FABP 
= 6.44 ±3.06 µg/L, (range 2-11 µg/L, median = 7 
µg/L); ALT = 198.67 ±122.89 U/L, (range 73-500 
U/L, median = 114 U/L) and bilirubin = 100.89 
±87.85 µmol/L, (range 17 - 337 µmol/L, median 
= 66 µmol/L). There was no significant difference 
between the concentration of H-FABP in the study 
group and controls; however, the concentrations of 
liver enzymes and protein (ALT and Bilirubin) were 
significantly elevated in the study group [Table 1].
Discussion 
Under normal conditions H-FABP is present in 
plasma in very low concentrations (< 5 µg/L), but 
it is significantly elevated upon cellular injury.18 
This makes the plasma estimation of H-FABP 
suitable for the early detection and quantification 
of myocardial tissue injury. However, this protein is 
not totally cardiac specific as it occurs in skeletal 
muscle in concentrations varying between 0.05-0.2 
mg/g wet weight of tissue, depending on muscle 
fibre type studied.5 It has also been reported in 
very low concentrations in tissues like the kidney, 
aorta, testes, mammary glands, placenta, brain, 
adrenal glands, adipose tissue, and stomach.2,3  The 
concentration of H-FABP in the study group was 
not statistically different from the control group. 
This finding leads to several assumptions. First, the 
Liver-FABP (L-FABP) is a separate factor with no 
or negligible cross-reactivity with H-FABP assays. 
Indeed, the cross-reactivity between these two 
proteins has been reported to be < 0.005.17 Second, 
the release of H-FABP from other tissues containing 
this protein (see above) is at best minimal in patients 
who have chronic liver diseases. Our study was 
the first of its kind to address the interference of 
chronic liver diseases on the normal concentrations 
of H-FABP. There are no data on this issue in the 
literature hence it is difficult to correlate our 
findings. 
In a previous study, we have shown major 
limitations for the use of H-FABP concentration for 
the diagnosis of myocardial injury in the presence 
of renal failure.19 The liver contains only L-FABP, 
but co-expression of H-FABP and L-FABP occurs 
in the kidney. Similarly, intestinal-type FABP 
(I-FABP) and L-FABP are found in intestines, and 
brain-type FABP (B-FABP) and H-FABP occur in 
the brain. Preliminary but promising applications 
of these proteins have been demonstrated for liver 
rejection, viability selection of kidneys from non-
heart-beating donors (NHBD), inflammatory and 
ischaemic bowel disease, traumatic brain injury 
and in the prevention of muscle injury in trained 
athletes.20 Measurement of H-FABP in the first 24 
hours after onset of symptoms may be potentially 
useful for the diagnosis of AMI; identification of 
patients who need reperfusion treatment early; 
identification of patients who reperfuse their infarct 
related artery; detection of re-infarction if it occurs 
early, and estimation of infarct size.21
Conclusion 
These data illustrate clearly that there is no significant 
interference with the normal concentration of 
H-FABP in the presence of chronic liver diseases, 
despite the significant elevation of liver enzymes 
and proteins. This is consistent with the reduced 
cross-reactivity between H-FABP and other FABP 
Table 1: Age and concentrations of marker proteins in the control and study groups
Control Group
(Blood donors)
Study Group
(Liver disease patients)  p value
Numbers n=20 n=10 - 
Age 63.8 ±8.0 58.33 ±7.2  (NS)
AlT 29.8 ±14.7 198.67 ±122.9  < 0.0005
Bilirubin 9.6 ±4.0 100.89 ±87.9  < 0.0001
H-FABP 6.86 ±2.2 6.44 ±3.1 (NS)
Legend: NS = not significant; ALT = alanine aminotransferase; H-FABP = Heart-type fatty acid binding-protein
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including L-FABP. These findings may support a 
useful role of H-FABP for the diagnosis of myocardial 
injury in patients with chronic liver diseases.
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عرص ةلاحو ةيدلج تافآ عم  ةلفط
غاب ِّصلا َُسلَس ةلاح نع ريرقت
يسيطفلا ةنمآ ،داوج مشاه ،يرزعلا لصيف ، يلئاولا دمحأ ،شيناغ اهدارونأ ،يبيهزلا ءانس
 دللجا لمشت ّيِبَصَعلا ِرِها َّظلا ِيمَدلأاب ةقلعتم ةددعتم ةزهجأ بيصي ضرلما .ةدئاس ةثارو وذو سنلجاب طبترم ردان يثارو ضرم غاب ِّصلا َُسلَس :صخللما
 .ثانلإا دنع ايريرس ةريغتم لاكشأ اذ نوكي امنيب ، روكذلا دنع لاتاق ضرلما نوكي ام ةداع .يزكرلما يبصعلا زاهلجاو نانسلأاو رفاظلأاو رعشلاو ينعلاو
 ةدلاولا يثيدح عرص ةلاحب )نامع ةنطلس( سوباق ناطلسلا ةعماج ىفشتسم ىلإ  تلخدأ رهشأ ةتس اهرمع ةلفط ةلاح نع اريرقت انه رشنن
    .ريرقتلا اذه يف تشقون ةيعيبط ريغ ةددعتم ةيبصعو ةينيع رهاظم  اهيدل و  هتطرفم وأ غابصلا ةصقان ةيدلج تافآب ةبوحصم
نامع،ةلاح ريرقت ،يبصع ضرم ،وتيلا يننلايلما صقن ،ةينيع ،عرص ،غابصلا سلس :تاملكلا حاتفم  
abstract: Incontinentia Pigmenti )IP(, )OMIM # 308300(, is a rare X-linked dominant condition. It is a multisystemic 
disease with neuroectodermal findings involving the skin, eyes, hair, nails, teeth, and central nervous system. It is usually 
lethal in males; the disease has variable expression in an affected female. We report the case of a 6 month old girl who 
presented at Sultan Qaboos University Hospital, Oman, with neonatal seizures and hypopigemented/hyperpigmented skin 
lesions. She had multiple ophthalmic abnormalities and neurological manifestations which are discussed in this report. 
Keywords: Incontinentia Pigmenti (IP); Seizures; Ophthalmic; Hypomelanosis of Ito; Neurologic diseases; Case report; 
Oman.
Departments of 1Ophthalmology, ²Child Health, ³Family and Community Health, and 4Radiology & Molecular Imaging, Sultan 
Qaboos University Hospital, Muscat, Sultanate of Oman
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Incontinentia pigmenti (IP) type 2, also known as Bloch-Sulzberger syndrome, is an inherited multisystem neurocutaneous disorder 
with a low incidence (1% of all neurocutaneous 
disorders).1 It is an X-linked dominant condition 
dominant inheritance. The disease is lethal in 
males, except in rare cases of somatic mosaicism, or 
mutations in IKBKG, and when the condition occurs 
in patients with Klinefelter syndrome.2,3 Typical 
skin lesions are seen in 100% of (IP) patients.2 Other 
manifestations include dental (90%), skeletal (40%), 
central nervous system (CNS) (40-50%) and ocular 
(35%) conditions.4,5 
Patients with IP frequently have systemic 
involvement, similar to the involvement in 
patients with hypomelanosis of Ito, including CNS 
manifestations. In patients with IP, cutaneous 
lesions undergo three stages, which may overlap.6
In this report, we discuss the dermatologic, 
neurological and ophthalmologic findings of a 6 
month old female who presented with early onset 
neonatal seizures and displayed hypopigmented/ 
hyperpigmented skin lesions. In addition, this child 
had characteristic ophthalmologic findings. 
Case Report
This 6 month old girl was born by spontaneous 
vaginal delivery to healthy non-consanguineous 
parents with two normal sons. She was referred 
to Sultan Qaboos University Hospital (SQUH), 
Oman, from a peripheral hospital for evaluation of 
abnormal skin lesions and seizures. 
She was reported to have had hyper/
hypopigmented skin lesions all over her body except 
the face since she was 6 days old. The skin lesions 
were noted to be of linear pattern over the upper 
and lower limbs and of a whorled pattern over 
the anterior and posterior chest wall. The mother 
denied the presence of any skin lesion at birth. Her 
examination showed evidence of hypotonia and 
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mild developmental delay with microcephaly where 
her head circumference was significantly below the 
third percentile for age. Her weight was below the 
third percentile, but her height was normal for age. 
Her tone was mildly decreased with normal reflexes 
and positive Babinski reflex. She had a normal 
visual following, but was not able to respond to 
sound clinically. Other systemic examinations were 
normal. 
The child developed clonic seizures at the 
age of 3.5 months and was commenced on oral 
phenobarbitone with good seizure control. The 
computed tomography (CT) scan of the brain 
(performed at a peripheral hospital) showed 
atrophy of the frontal horns with corpus callosum 
agenesis. A chromosomal study showed a normal 
female karyotype. 
At SQUH, a magnetic resonance imaging (MRI) 
of the brain showed hypoplasia of the corpus 
callosum and hypomyelination with perivetricular 
white matter hyperintense signal abnormalities 
[Figures 1a and 1b]. Electrophysiological testing 
showed positive visual evoked potential (VEP) 
responses using a flash stimulation, but negative 
responses for brain stem auditory evoked potentials 
(BAEP). 
An ophthalmologic evaluation was performed 
at the age of 5 months. The child was able to follow 
and fixate with both eyes. There was no obvious 
nystagmus, ocular deviation or ptosis. Further 
examination under anaesthesia revealed bilateral 
inferior superficial epithelial corneal erosions; there 
were no stromal infiltrates or any increase in corneal 
thickness. The corneal size was normal for age in 
both eyes. She had a bilateral mild form of persistent 
pupillary membrane. She had a normal red reflex 
and normal reacting pupils with no evidence of any 
relative afferent defect. The intraocular pressure 
was 24mmHg in both eyes. No major refractive 
error was noted. A dilated fundus examination 
showed a large optic disc cup (disc cup ratio of 
0.8 in both eyes). There were diffuse non-specific 
retinal pigment epithelial changes. The peripheral 
retinal examination revealed areas of fibrovascular 
proliferation with no evidence of retinal traction 
or detachment [Figures 2a and 2b]. The child was 
started on latanoprost 0.05% eye drops q.h.s. in 
both eyes with regular follow-ups at the eye clinic. 
Histological studies of the skin lesions and genetic 
studies were scheduled; unfortunately, the child 
died from status epilepticus at a peripheral hospital 
before  these studies could be undertaken.
Discussion
IP is characterized by abnormalities of the tissues 
and organs embryologically derived from ectoderm 
and neuroectoderm.4 The diagnosis of IP is made on 
Figure 1a: Magnetic resonance imaging scan: Sag 
T1W SE, midline. There is hypoplasia of the corpus 
callosum. Optic chiasm, pituitary gland and midbrain 
are grossly normal.
Figure 1b: Magnetic resonance imaging scan: axial 
T2W SE at level of basal ganglia. There is bilateral 
hyperintense signal abnormality in the periventricular 
white matter associated with brain atrophy. No 
imaging findings of acute ischemia or cortical necrosis
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clinical grounds aided by histological confirmation. 
The skin lesions may follow the Blaschko lines and 
the initial appearance of skin lesions can be seen 
immediately after birth or early during the neonatal 
period. Timely recognition of IP by pediatricians 
and dermatologists is therefore crucial. IP overlaps 
with hypomelanosis of Ito, which is a syndrome 
with hypopigmented whorls of the skin along the 
Blaschko lines, especially when it presents at the stage 
of skin hypopigmentaion. Chromosomal mosaicism 
is believed to be the reason that hypomelanosis 
of Ito is so varied in phenotype. Certain genes, 
namely, those on 9q33-qter, 15q11-q13, and Xp11, 
have been implicated in hypomelanosis of Ito; 
however, no consensus exists about the identity of 
the hypomelanosis of Ito gene.5, 6
 In around 40-50% of IP cases, there may be 
neurological problems such as seizures, spasticity, 
or mental retardation.1 Seizure can be the first 
manifestation of the disease.2 Abnormal tooth 
eruption, malformed tooth crowns, and patchy 
alopecia are commonly seen. Retinal dysplasia can 
sometimes lead to visual problems.
The diagnosis of IP is also aided by family 
history and a history of miscarriages of the male 
gender as the disease is prenatally lethal in males. 
The disease is caused by a genomic rearrangement 
of the gene for NEMO, or nuclear factor kappa B 
essential modulator (IKBKG-IKK gamma). The 
defect in the X chromosome is proximal to the 
gene for factor VIII at Xq28. 7, 8 Although this child 
was the first affected in her family with two normal 
male siblings and no previous miscarriages in the 
family, she had hypopigmented/hyperpigmented 
lesions suggestive of the disease. Initially, the 
diagnosis was not entertained, despite the skin 
manifestations, until her presentation with partial 
seizures. The possibility of hypomelanosis of Ito 
diagnosis was also kept in mind though further 
evidence of neurological involvement and the eye 
manifestations were suggestive of IP.
The skin lesions in IP manifest in stages that 
evolve sequentially.7 The onset and duration of each 
stage vary among individuals; not all individuals 
experience all four stages.1 Typically four 
dermatological stages are seen: 1) the bullous stage; 
early blistering with eosinophilia; 2) the verrucous 
stage: eruption of hyperkeratotic lesions; 3) the 
hyperpigmentation stage: hyperpigmentation along 
the lines of Blaschko and, finally, 4) the atretic stage: 
dermal scarring. In the vast majority of cases, the 
onset of skin changes is before 6 weeks of age.1 Our 
patient had the third stage which was not preceded by 
the first or second stages. The differential diagnosis 
of patients presenting with stage 3 and 4 skin lesions 
includes: hypomelanosis of Ito; IP achromians; focal 
dermal hypoplasia syndrome (Goltz syndrome) and 
X-linked dominant chondrodysplasia punctata. 
In IP, variable clinical expressions of CNS 
involvement are seen. They include epilepsy, mental 
retardation, hemiparesis, spasticity, microcephaly, 
and cerebellar ataxia.5 The pathogenesis of the CNS 
lesion in IP remains unclear.9,10,11 Recent brain-
imaging techniques, such as MRI and magnetic 
resonance angiogram (MRA), have provided a better 
understanding of the nature of the CNS pathology. 
These imaging studies have demonstrated scattered 
cortical neuronal and white-matter necrosis, 
Figure 2a: RetCam fundus photo of the right eye 
showing large disc cupping and epiretinal pseudoglial 
tissue superior to the fovea (arrow)
Figure 2b: RetCam fundus photo of the right eye 
showing large disc cupping and epiretinal pseudoglial 
tissue superior to the fovea (arrow)
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hypoplasia of the corpus callosum, periventricular 
white-matter cystic lesions, neuronal heterotopia, 
and cerebral atrophy.12, 13
Our patient had evidence of hypoplasia of 
the corpus callosum and decreased myelination 
of the white matter and, clinically, both seizures 
and developmental delay. The presence of CNS 
involvement, such as seizures, in the neonatal 
period is a poor prognostic sign.4, 6, 7
Ocular abnormalities occur in 35% or more of 
patients and 19% are at risk of severe visual loss in 
one or both eyes.14,15  A wide range of ophthalmologic 
findings are seen in patients with IP.7 The commonest 
reported are strabismus in 18.2% and a retrolental 
mass or retinal pseudoglioma in 15.4%.
There are previous reported cases in literature 
of multiple corneal abnormalities including 
megalocornea, corneal oedema, band keratopathy, 
bullus keratopathy, variable corneal epithelial and 
stromal changes and iridocorneal attachments.10 
The corneal findings in this child were superficial 
punctuate epithelial erosion and features suggestive 
of an inflammatory noninfectious process. 
The posterior segment findings may include 
multiple retinovascular abnormalities (such as 
retinal vascular tortuosity, macular capillary 
dropout, peripheral arteriovenous shunts, retinal 
neovascularisation, and vitreous haemorrhage). 
Subsequently, preretinal fibrosis, pseudoglioma 
and traction retinal detachment can result.14 This 
child had findings suggestive of what looked like 
pseudogliomas in both eyes [Figures 2a and 2b] 
and peripheral fibrovascular lesions OU with no 
evidence of retinal traction. 
Holstrom proposed a scheme for following 
patients with IP and eye manifestations. They 
recommended that eyes should be examined soon 
after birth, and then at least monthly for three to 
four months, at three-month intervals for one 
year, and twice yearly up to three years. They also 
recommended that the frequency of examinations 
should be increased in children with retinal disease. 
If, at three years of age, no abnormalities, refractive 
errors or strabismus are found, they state that the 
follow-up can cease.16 
During the ophthalmic follow-up, visual 
functions should be assessed by both clinical and 
electrophysiological measures including VEP and 
electroretinography (ERG).16,17  Any significant 
refractive errors should be corrected and amblyopia 
therapy as well as strabismus treatment should be 
provided.18,19 Cryotherapy or laser  photocoagulation 
should be applied for active peripheral retinal 
abnormalities and tractional retinal detachment 
should be treated surgically. 
Conclusion
In summary,  IP or Bloch-Sulzberger syndrome 
is a rare X-linked dominant syndrome. It has 
multisystemic involvement that includes the skin, 
central nervous system and eyes. In neurocutaneous 
syndromes, multidisciplinary care with periodic 
consultations with a paediatric ophthalmologist, 
neurologist and other specialists depending 
on the associated anomalies are  essential. The 
differentiation between hypomelanosis of Ito and 
IP can be difficult as the two disorders overlap 
considerably. Clinicians need to be aware of 
the variable manifestations of this disease for a 
timely and multidisciplinary management of such 
patients.
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